Baker Tilly was contacted by a large, multinational molecular diagnosis testing company to develop and execute a strategic publication plan that would demonstrate the cost-effectiveness of one of its genetic tests.
The client needed to translate previously generated cost-effectiveness data into meaningful insights for the scientific community. Additionally, the client wanted to increase industry awareness of the value proposition of their product.
Understanding the client's goals, Baker Tilly developed an analysis of real-world data (RWD), resulting in positive cost-effectiveness findings associated with the product. With these findings, a comprehensive publication strategy was developed, targeting key audiences of high-impact journals.
Baker Tilly’s RWD analysis directly contributed to having a large, national health plan cover the product and a peer-reviewed scientific journal publish a manuscript communicating the cost-effectiveness of the client’s product. This manuscript enabled the client to increase its market presence and strengthen the scientific literature supporting its product’s value.